跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 13 天前AI 评分20

亚盛医药提交 Form 6-K,披露将在 2026 年 ASH 年会上展示多项试验数据

6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)

AI 导读

亚盛医药集团国际公司提交 Form 6-K,披露公司将于 2026 年 ASH 年会展示多项试验数据,其中包括 APG-5918 的口头报告。相关新闻稿日期为 11 月 4 日,公告日期为 11 月 5 日,分别作为附件 99.1 和 99.2 提交。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

 
 

On November 4, 2026, Ascentage Pharma Group International issued a press release entitled, “ASCENTAGE PHARMA TO PRESENT DATA FROM MULTIPLE TRIALS, INCLUDING AN ORAL PRESENTATION OF APG-5918, AT ASH ANNUAL MEETING 2026” and posted an announcement dated November 5, 2026 entitled, “ASCENTAGE PHARMA TO PRESENT DATA FROM MULTIPLE TRIALS, INCLUDING AN ORAL PRESENTATION OF APG-5918, AT ASH ANNUAL MEETING 2026.” Copies of the press release and announcement are furnished as Exhibits 99.1 and 99.2 to this Report.

1
 

INDEX TO EXHIBITS

Exhibit Number    Exhibit Title
99.1     Press release dated November 4, 2026
99.2   Announcement dated November 5, 2026
2
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  ASCENTAGE PHARMA GROUP INTERNATIONAL
     
Date: November 5, 2026 /s/ Dajun Yang
  Name: Dajun Yang
  Title: Chief Executive Officer
3

来源:SEC EDGAR · 本站存档